Anti-SARS-Cov-2 antibodies derived from 2GHW
This disclosure provides antibodies and antigen-binding fragments that are derived from 2ghw and that can be administered to an individual that is infected or suspected of being infected with a virus. Antibodies and antigen-binding fragments provided herein can be capable of treating or curing the virus, and which may provide protection against the virus for up to several weeks. Antibodies and antigen-binding fragments provided herein can be used to diagnose a SARS-Cov-2 infection.
1. An antibody or an antigen-binding fragment that selectively binds to a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), that comprises a variable heavy chain (VH) complementarity determining region 1 (CDR1) having an amino acid sequence of SEQ ID NO: 39; a VH CDR2 having an amino acid sequence of SEQ ID NO: 53; a VH CDR3 having an amino acid sequence of SEQ ID NO: 68; a variable light chain (VL) CDR1 having an amino acid sequence of SEQ ID NO: 7; a VL CDR2 having an amino acid sequence of SEQ ID NO: 15; and a VL CDR3 having an amino acid sequence of SEQ ID NO: 25.
2. The antibody or the antigen-binding fragment of claim 1 , that comprises a VH having an amino acid sequence that is at least 90% identical to SEQ ID NO: 81 and a VL having an amino acid sequence that is at least 90% identical to SEQ ID NO: 93.
3. The antibody or the antigen-binding fragment of claim 2 , wherein the antibody comprises a monoclonal antibody, a grafted antibody, a chimeric antibody, a human antibody, or a humanized antibody.
4. The antibody or the antigen-binding fragment of claim 2 , wherein the binding affinity is less than 50 nanomolar (nM).
5. The antibody or the antigen-binding fragment of claim 2 , wherein the antigen-binding fragment comprises a Fab, a Fab′, a F(ab′) 2 , a variable fragment (Fv), a triabody, a tetrabody, a minibody, a bispecific F(ab′) 2 , a trispecific F(ab′) 2 , a diabody, a bispecific diabody, a single chain variable fragment (scFv), a scFv-Fc, a Fab-Fc, a VHH, or a bispecific scFv.
6. A method of preventing or treating a SARS-CoV-2 viral infection or COVID19 in a subject in need thereof, comprising administering to the subject the antibody or the antigen-binding fragment of claim 1 .
7. The method of any claim 6 , that further comprises administering one or more additional therapies or drugs to the subject.
8. A method of diagnosing a subject as being infected with a SARS-CoV-2 virus or suspected of being infected with a SARS-CoV-2 virus, the method comprising contacting a sample obtained from the subject with the antibody or the antigen-binding fragment of claim 1 ; detecting the presence or absence of an antibody/SARS-CoV-2 virus complex or an antigen-binding fragment/SARS-CoV-2 virus complex; and diagnosing the subject as being infected with a SARS-Cov-2 virus when the presence of the antibody/SARS-CoV-2 virus complex or the antigen-binding fragment/SARS-CoV-2 virus complex is detected.
9. The method of claim 8 , wherein the sample comprises a nasal swab, a tissue sample, saliva, or blood.
10. The method of claim 8 , wherein detecting the presence or absence of the antibody/SARS-CoV-2 virus complex or the antigen-binding fragment/SARS-CoV-2 virus complex comprises an enzyme linked immunosorbent assay (ELISA), an immunospot assay, a lateral flow assay, flow cytometry, immunohistochemistry, or a western blot.
11. An antibody or an antigen-binding fragment that selectively binds to a SARS-CoV-2, that comprises a VH having an amino acid sequence of SEQ ID NO: 81 and a VL having an amino acid sequence of SEQ ID NO: 93.
12. The antibody or the antigen-binding fragment of claim 1 , wherein the binding affinity is less than 50 nM.
13. The antibody or the antigen-binding fragment of claim 1 , wherein the antigen-binding fragment comprises a Fab, a Fab′, a F(ab′) 2 , a variable fragment (Fv), a triabody, a tetrabody, a minibody, a bispecific F(ab′) 2 , a trispecific F(ab′) 2 , a diabody, a bispecific diabody, a single chain variable fragment (scFv), a scFv-Fc, a Fab-Fc, a VHH, or a bispecific scFv.
14. The antibody or the antigen-binding fragment of claim 1 , wherein the antibody is an IgG, an IgM, an IgE, an IgA, an IgD, or is derived therefrom.
15. The antibody or the antigen-binding fragment of claim 2 , wherein the antibody is an IgG, an IgM, an IgE, an IgA, an IgD, or is derived therefrom.
16. An antibody or an antigen-binding fragment that selectively binds to a SARS-CoV-2, that comprises:
(i) a VH CDR1 having an amino acid sequence of SEQ ID NO: 41, a VH CDR2 having an amino acid sequence of SEQ ID NO: 55, a VH CDR3 having an amino acid sequence of SEQ ID NO: 70, a VL CDR1 having an amino acid sequence of SEQ ID NO: 9, a VL CDR2 having an amino acid sequence of SEQ ID NO: 14, and a VL CDR3 having an amino acid sequence of SEQ ID NO: 23;
(ii) a VH CDR1 having an amino acid sequence of SEQ ID NO: 32, a VH CDR2 having an amino acid sequence of SEQ ID NO: 46, a VH CDR3 having an amino acid sequence of SEQ ID NO: 61, a VL CDR1 having an amino acid sequence of SEQ ID NO: 4, a VL CDR2 having an amino acid sequence of SEQ ID NO: 13, and a VL CDR3 having an amino acid sequence of SEQ ID NO: 20;
(iii) a VH CDR1 having an amino acid sequence of SEQ ID NO: 36, a VH CDR2 having an amino acid sequence of SEQ ID NO: 50, a VH CDR3 having an amino acid sequence of SEQ ID NO: 65, a VL CDR1 having an amino acid sequence of SEQ ID NO: 6, a VL CDR2 having an amino acid sequence of SEQ ID NO: 14, and a VL CDR3 having an amino acid sequence of SEQ ID NO: 23; or
(iv) a VH CDR1 having an amino acid sequence of SEQ ID NO: 30, a VH CDR2 having an amino acid sequence of SEQ ID NO: 44, a VH CDR3 having an amino acid sequence of SEQ ID NO: 59, a VL CDR1 having an amino acid sequence of SEQ ID NO: 4, a VL CDR2 having an amino acid sequence of SEQ ID NO: 13, and a VL CDR3 having an amino acid sequence of SEQ ID NO: 20.